FrancophonIA/ELRC3.0 huggingface dataset:
English: Pharmacotherapeutic group: Antibacterial for systemic use.
Danish: Terapeutisk klassifikation Antibakterielt middel til systemisk brug.
English: The 6.25 mg strength is a round, biconvex, white, film-coated tablet.
Danish: Tabletten er en rund, biconvex, hvid og filmovertrukket.
English: Concurrent use of fluoroquinolones with oral cyclosporin is contraindicated.
Danish: Samtidig brug af fluorquinoloner med oral cyclosporin er kontraindiceret.
English: The dosage of theophylline should be reduced when used concurrently with fluoroquinolones.
Danish: Dosering af theophyllin bør reduceres ved samtidig behandling med fluorquinoloner.
English: In dogs that receive an overdose greater than 22.5 mg/kg, salivation, soft and/or mucoid faeces and vomiting may be observed.
Danish: Hunde der får mere end 22,5 mg/kg kan savle og have blød og/eller mucoid fæces.
English: The mode of action of the fluoroquinolones is through interference with the bacterial enzyme DNA gyrase which is needed for the synthesis of bacterial DNA.
Danish: Fluorquinoloner virker ved at påvirke bakteriernes enzym DNA-gyrase, som er nødvendig i syntesen af bakterie-DNA.
English: Concurrent administration with metal cations such as those contained in antacids made with magnesium hydroxide or aluminium hydroxide, or multivitamins containing iron or zinc, has been reported to dramatically decrease the bioavailability of fluoroquinolones.
Danish: Samtidig indgift af metal cationer som indeholdt i f.eks. antacida fremstillet med magnesiumhydroxid eller aluminiumhydroxid, eller multivitaminpræparater der indeholder jern eller zink rapporteres at reducere biotilgængeligheden af fluorquinoloner voldsomt.
English: Treatment of uncomplicated bacterial cystitis due to susceptible strains of E coli and Proteus mirabilis, and treatment of skin and associated soft tissue infections (wounds and abscesses), associated with bacteria susceptible to orbifloxacin.
Danish: Behandling af ukompliceret bakteriel cystitis hos hunde forårsaget af følsomme stammer af E. coli og Proteus mirabilis, samt behandling af hud og bløddelsinfektioner (sår og abcesser) forårsaget af bakterier følsomme for orbifloxacin.
English: Schering-Plough S.A. 63, Agiou Dimitriou Str. 174 55 Alimos Athens
Danish: Grækenland Schering-Plough S.A. 63, Agiou Dimitriou Str. 174 55 Alimos Athen
English: Orbifloxacin is a synthetic broad spectrum antibacterial agent from the class of fluoroquinolone carboxylic acid derivatives.
Danish: Orbifloxacin er et syntetisk, bredspektret antibakterielt middel i familie med fluorquinolon carboxylsyrederivaterne.
English: 4.1 Pharmacodynamic properties
Danish: 4.1 Farmakodynamiske egenskaber
English: 5.10 Special warnings for target species
Danish: 5.10 Særlige advarsler for hver dyreart
English: Presentations:
Danish: Præsentationsformer:
English: Concurrent administration of fluoroquinolones may increase the action of oral anticoagulants.
Danish: Samtidig administration af fluorquinoloner kan øge effekten af orale antikoagulanter.
English: Cimetidine has been shown to interfere with the metabolism of fluoroquinolones and should be used with care when used concurrently.
Danish: Cimetidin har vist sig at interfere med metaboliseringen af fluorquinoloner, hvorfor forsigtighed bør udvises ved samtidig anvendelse.
English: By 24 hours, urine concentrations of orbifloxacin are approximately 40 g/ml.
Danish: 24 timer efter behandling er koncentrationen af orbifloxacin i urinen ca. 40 g/ml.
English: Orbifloxacin is bactericidal with activity against mainly Gram-negative bacteria but also against some Gram-positive bacteria.
Danish: Orbifloxacin har baktericid effekt på især gramnegative, men også visse grampositive bakterier.
English: Use of fluoroquinolones such as orbifloxacin should be based on susceptibility testing and take into account official and local antimicrobial policies.
Danish: Fluorqinoloner bør kun anvendes efter udført følsomhedstest og under hensyntagen til officielle og lokale anbefalinger vedr.
English: The 25 mg strength tablet is modified capsule shaped with an EZ-break score on one side and the Schering-Plough “SP” logo engraved on each half of the other side.
Danish: Tabletten er kapselformet med en “Easy break” delekærv på den ene side og et Schering-Plough “SP” logo indgraveret på hver halvdel af den anden side.
English: As no specific studies have been conducted in pregnant dogs, it is not recommended to administer Orbax tablets to dogs during pregnancy and lactation.
Danish: Idet der ikke er udført undersøgelser på hunde i avl, kan det ikke anbefales at bruge Orbax til drægtige og diegivende tæver eller til avlshunde.
English: PHARMACEUTICAL DATA
Danish: FARMAKOLOGISKE OPLYSNINGER
English: United Kingdom Schering-Plough Ltd Schering-Plough House Shire Park
Danish: Det Forenede Kongerige Schering-Plough Ltd Schering-Plough House Shire Park
English: PHARMACEUTICAL FORM Film-coated tablet
Danish: LÆGEMIDDELFORM Filmovertrukne tabletter
English: Essex Tierarznei Ndl. der Essex Pharma GmbH Thomas-Dehler-Str. 27 81737 Munchen Germany
Danish: Essex Tierarznei Ndl. Der Essex Pharma GmbH Thomas-Dehler-Str. 27
English: 5.2 Indications for use
Danish: 5.2 Indikationer
English: In tolerance studies in dogs, using up to 5 times the maximum recommended dosage of 7.5mg/kg, the product is well tolerated.
Danish: Dosering med op til 5 x den maksimale anbefalede dosis på 7,5 mg/kg tolereres godt.
English: The oral bioavailability of orbifloxacin in dogs is approximately 100%.
Danish: Biotilgængeligheden efter peroral administration af orbifloxacin formuleret i tabletform er tæt på 100%.
English: 6.6 Special Precautions for disposal of unused product or waste materials, if any Any unused product or waste material should be disposed of in accordance with national requirements.
Danish: Eventuelle ubrugte lægemidler eller affald fra sådanne produkter skal destrueres i overensstemmelse med de lokale krav.
English: To ensure a correct dosage, body weight should be accurately determined to avoid underdosing.
Danish: Hunden bør vejes inden behandlingen påbegyndes for at undgå underdosering.
English: Schering-Plough NV/SA Rue de Stallesstraat 73 1180 Brussels Belgium
Danish: Schering-Plough NV/SA Rue de Stalle 73 / Stallesstraat 73 1180 Bruxelles
English: The recommended dose of Orbax Tablets is 2.5 mg/kg bodyweight for treatment of bacterial cystitis and 7.5 mg/kg bodyweight for treatment of skin and associated soft tissue infections administered once daily.
Danish: Den anbefalede dosis af Orbax tabletter er 2,5 mg/kg legemsvægt til behandling af bakteriel cystitis og 7,5 mg/kg til behandling af hud- og bløddelsinfektion 1 gang dagligt.
English: Following once daily multiple dosing at 7.5 mg/kg, skin concentrations of orbifloxacin in diseased skin exceed concentrations in plasma.
Danish: Ved gentagne doseringer af 7,5 mg/kg en gang dagligt opnås koncentrationer af orbifloxacin i den syge hud der overstiger plasmakoncentrationen.
English: 5.1 Target species
Danish: 5.1 Dyrearter
English: 6.5 Name or style and permanent address or registered place of the business of the holder of the authorisation to place the product on the market Schering-Plough Limited
Danish: 6.5 Navn eller firmanavn og adresse eller hovedsæde for indehaveren af markedsføringstilladelsen
English: 5.4 Undesirable Side effects
Danish: 5.4 Bivirkninger
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Orbifloxacin 75 mg per tablet
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Orbifloxacin 75 mg pr. tablet
English: 5.7 Interactions with other medicaments
Danish: 5.7 Interaktioner
English: 25 mg
Danish: à 25 mg
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Orbifloxacin 25 mg per tablet
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Orbifloxacin 25 mg pr. tablet
English: It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions which have responded poorly to other classes of antimicrobials.
Danish: Det er vigtigt at brugen af fluorquinoloner reserveres til infektioner forårsaget af bakterier med manglende eller nedsat følsomhed for andre klasser af antibiotika.
English: 75 mg
Danish: à 75 mg
English: 5.6 Use during pregnancy and lactation
Danish: 5.6 Drægtighed og diegivning
English: Schering-Plough Veterinaire 92 rue Baudin
Danish: Schering-Plough Vétérinaire 92, rue Baudin 92300 Levallois-Perret Frankrig
English: In field trials with orbifloxacin, canine pyoderma was not clinically evaluated; consequently, dogs with this skin condition should be excluded from therapy.
Danish: I kliniske studier med orbifloxacin blev effekten på hunde med pyodermi ikke evalueret.
English: 6.25 mg
Danish: à 6,25 mg
English: After a 2.5 mg/kg dose, urine concentrations of orbifloxacin are approximately 100 g/ml for approximately 12 hours after dosing.
Danish: Ved en dosering på 2,5 mg/kg er koncentrationen af orbifloxacin i urinen ca. 100 g/ml i de første.
English: 5.5 Special Precautions for use
Danish: 5.12 Særlige forsigtighedsregler for brugeren
English: Dosing Chart for ORBAX 75 mg Tablets (2.5 mg/kg once daily)
Danish: Doseringskort for Orbax vet. tabletter (2,5 mg/kg 1 x dagligt)
English: NAME OF VETERINARY MEDICINAL PRODUCT ORBAX 6.25 mg film-coated tablet
Danish: VETERINÆRLÆGEMIDLETS NAVN Orbax Vet. 6,25 mg
English: 1 card of 8 dividable tablets (8 tablets)
Danish: PVDC blisterkort á 8 tabletter
English: NAME OF VETERINARY MEDICINAL PRODUCT ORBAX 75 mg film-coated tablet
Danish: VETERINÆRLÆGEMIDLETS NAVN Orbax Vet. 75 mg
English: Schering-Plough House
Danish: Schering-Plough A/S
English: NAME OF VETERINARY MEDICINAL PRODUCT ORBAX 25 mg film-coated tablet
Danish: VETERINÆRLÆGEMIDLETS NAVN Orbax Vet. 25 mg
English: # of 6.25 mg tablets
Danish: Orbax 6,25 mg
English: 10 cards of 8 dividable tablets (80 tablets)
Danish: PVDC blisterkort á 80 tabletter
English: No special precautions for storage are required
Danish: 6.3 Særlige opbevaringsforhold Ingen.
English: The tablets are packaged in PVDC blister with aluminium foil lidding 6.25 mg tablet carton contains;
Danish: PVDC blisterkort á 100 tabletter i karton.
English: 1 card of 10 tablets (10 tablets)
Danish: PVDC blisterkort á 10 tabletter i karton
English: 6.4 Nature and content of container
Danish: 6.4 Emballage
English: # of 6.25 mg tablets Dosing Chart for ORBAX 6.25 mg Tablets (7.5 mg/kg once daily) Weight of Dog (kg)
Danish: Doseringskort for Orbax vet. tabletter (7,5 mg/kg 1 x dagligt) 2,5 kg 5 kg 10 kg 15 kg 20 kg 25 kg 30 kg 45 kg 60 kg
English: 10 cards of 10 tablets (100 tablets)
Danish: PVDC blisterkort á 100 tabletter i karton
English: QUALITATIVE AND QUANTITATIVE COMPOSITION OOrbifloxacin 6.25 mg per tablet Film coating containing titanium dioxide (E171)
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Orbifloxacin 6,25 mg pr. tablet
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lixiana on 19 June 2015.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Lixiana den 19. juni 2015.
English: The full EPAR for Lixiana can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Lixiana findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Lixiana.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Lixiana.
English: Lixiana is available as tablets (15, 30 and 60 mg) and can only be obtained with a prescription.
Danish: Lixiana leveres som tabletter (15, 30 og 60 mg) og udleveres kun efter recept.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Lixiana's benefits are greater than its risks and recommended that it be approved for use in the EU.
Danish: Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Lixiana opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: What measures are being taken to ensure the safe and effective use of Lixiana?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Lixiana?
English: Lixiana contains the active substance edoxaban.
Danish: Lixiana indeholder det aktive stof edoxaban.
English: Dose adjustments may also need to be made in patients who are switched between Lixiana and other anticoagulant medicines.
Danish: Dosisjustering kan desuden være nødvendig hos patienter, der skifter mellem Lixiana og andre blodfortyndende lægemidler.
English: It is not intended to provide practical advice on how to use Lixiana.
Danish: Det er ikke en praktisk vejledning i, hvordan Lixiana bør anvendes.
English: Why is Lixiana approved?
Danish: Hvorfor blev Lixiana godkendt?
English: What is Lixiana and what is it used for?
Danish: Hvad er Lixiana, og hvad anvendes det til?
English: In the treatment and prevention of blood clots in patients with DVT or pulmonary embolism, Lixiana was also found to be as effective as warfarin, in a study involving over 8,200 patients.
Danish: Til behandling og forebyggelse af blodpropper hos patienter med DVT eller lungeemboli var Lixiana desuden lige så effektivt som warfarin i en undersøgelse med over 8 200 patienter.
English: What are the risks associated with Lixiana?
Danish: Hvilke risici er der forbundet med Lixiana?
English: Lixiana must not be used in patients who are actively bleeding, have liver diseases that affect blood clotting, have severe uncontrolled high blood pressure or who have a condition putting them at significant risk of major bleeding.
Danish: Lixiana må ikke anvendes hos patienter med aktiv blødning, leversygdomme, der påvirker blodets størkning, svært ukontrolleret højt blodtryk eller sygdomme, der medfører væsentlig risiko for større blødninger.
English: For more information about treatment with Lixiana, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Lixiana, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: When another recommended definition of the type of stroke was used, embolism or stroke due to blood clots was seen in 143 patients given Lixiana (0.9%) and 157 given warfarin (1%).
Danish: Når der blev anvendt en anden anbefalet definition af typen af slagtilfælde, optrådte der emboli eller slagtilfælde som følge af blodpropper hos 143 patienter, der fik Lixiana (0,9 %) og hos 157 (1 %) af dem, der fik warfarin (1 %).
English: It must also not be used in pregnant or breastfeeding women or in patients also being treated with another anticoagulant.
Danish: Det må heller ikke anvendes hos gravide eller ammende kvinder eller hos patienter, der sideløbende er i behandling med et andet blodfortyndende lægemiddel.
English: The most common side effects with Lixiana (which may affect up to 1 in 10 people) are bleeding from skin and soft tissues, nose bleeds (epistaxis) and the vagina.
Danish: De hyppigste bivirkninger ved Lixiana (som optræder hos op til 1 ud af 10 personer) er blødning fra hud og underliggende væv, næseblødning (epistaxis) og blødning i skeden.
English: • to prevent stroke (caused by blood clots in the brain) and systemic embolism (blood clots in other organs) in patients with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart).
Danish: • til forebyggelse af slagtilfælde (som følge af blodpropper i hjernen), og blodpropper i andre organer (systemisk emboli) hos patienter med uregelmæssige hurtige sammentrækninger af hjertets forkamre (ikkevalvulær atrieflimren).
English: The active substance in Lixiana, edoxaban, is a ‘factor Xa inhibitor'.
Danish: Det aktive stof i Lixiana, edoxaban, er en faktor Xa-hæmmer.
English: Other common side effects are anaemia (low levels of red blood cells), rash, itching, headache, dizziness, belly pain and abnormal results in tests of liver function.
Danish: Andre hyppige bivirkninger er lavt antal røde blodlegemer (anæmi), udslæt, kløe, hovedpine, svimmelhed, mavesmerter og abnorme leverfunktionsprøver.
English: For the full list of all side effects reported with Lixiana, see the package leaflet.
Danish: Den fuldstændige liste over indberettede bivirkninger ved Lixiana fremgår af indlægssedlen.
English: Lixiana is an anticoagulant medicine (a medicine that prevents blood clotting) used in adults:
Danish: Lixiana er et blodfortyndende lægemiddel (et antikoagulans) til forebyggelse af blodpropper.
English: Lixiana has been shown to be as effective as the standard anticoagulant warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation.
Danish: Lixiana er påvist at være lige så effektivt som det almindeligt anvendte blodfortyndende lægemiddel warfarin til at forebygge slagtilfælde og systemisk emboli ved atrieflimmer.
English: For practical information about using Lixiana, patients should read the package leaflet or contact their doctor or pharmacist.
Danish: Hvis du ønsker praktisk vejledning om anvendelsen af Lixiana, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
English: How is Lixiana used?
Danish: Hvordan anvendes Lixiana?
English: The company that markets Lixiana will provide educational materials for doctors prescribing the medicine and an alert card for patients, explaining the risks of bleeding with the medicine and how to manage them.
Danish: Virksomheden, der markedsfører Lixiana, skal udlevere oplysningsmateriale til læger, som ordinerer lægemidlet, og advarselskort til patienterne.
English: The medicine has been shown to be at least as effective as warfarin in reducing stroke rates in patients with atrial fibrillation and in preventing further episodes of DVT or pulmonary embolism.
Danish: Det er påvist, at lægemidlet er mindst lige så effektivt som warfarin til at nedsætte forekomsten af slagtilfælde hos patienter med atrieflimren og forebygge gentagne episoder med dyb venetrombose eller blodpropper i lungerne.
English: What benefits of Lixiana have been shown in studies?
Danish: Hvilke fordele viser undersøgelserne, at der er ved Lixiana?
English: The main measure of effectiveness was the rate of stroke or systemic embolism among the patients each year.
Danish: Virkningen blev hovedsagelig målt på den årlige forekomst af slagtilfælde eller af blodpropper i hele kroppen hos patienterne.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lixiana have also been included in the summary of product characteristics and the package leaflet.Other information about Lixiana
Danish: Der er desuden anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge med henblik på sikker og effektiv anvendelse af Lixiana.
English: How does Lixiana work?
Danish: Hvordan virker Lixiana?
English: A first systemic embolism or stroke occurred in 182 patients given standard doses of Lixiana and in 232 of those given warfarin, corresponding to annual rates for these events of around 1.2% and 1.5% respectively.
Danish: Blandt de patienter, der fik sædvanlige doser af Lixiana, optrådte der systemisk emboli eller slagtilfælde hos 182 sammenholdt med 232 af dem, der fik warfarin.
English: However, the trend for its benefits in preventing stroke in atrial fibrillation to be less clear in those patients with high creatinine clearance (good kidney function) was considered to require further study.
Danish: Hos patienter med god nyrefunktion (høj kreatininclearance) er der dog mindre klar tendens til gavnlig virkning af lægemidlet til forebyggelse af slagtilfælde ved atrieflimmer.
English: Grepid can be given to the following groups of patients:
Danish: Grepid kan gives til følgende patientgrupper:
English: The European Commission granted a marketing authorisation valid throughout the EU for Grepid to Pharmathen S.A. on 28 July 2009.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Grepid til Pharmathen S.A. den 28. juli 2009.
English: Other information about Grepid:
Danish: Andre oplysninger om Grepid:
English: The standard dose of Grepid is one 75 mg tablet once a day, taken with or without food.
Danish: Standarddosis af Grepid er 75 mg en gang dagligt med eller uden et måltid.
English: The Committee recommended that Grepid be given marketing authorisation.
Danish: Udvalget anbefalede udstedelse af markedsføringstilladelse for Grepid.
English: The full EPAR for Grepid can be found here.
Danish: Den fuldstændige EPAR for Grepid findes her.
English: What are the benefit and risk of Grepid?
Danish: Hvilken fordel og risiko er der forbundet med Grepid?
English: Grepid clopidogrel EPAR summary for the public
Danish: Grepid clopidogrel EPAR - sammendrag for offentligheden
English: Grepid is a ‘generic medicine'.
Danish: Grepid er et ‘generisk lægemiddel'.
English: Grepid can be started between a few days and 35 days after the attack;
Danish: Behandling med Grepid kan påbegyndes få dage efter anfaldet og indtil 35 dage efter,
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Grepid has been shown to have comparable quality and to be bioequivalent to Plavix.
Danish: Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at Grepid i overensstemmelse med EU-kravene har vist sig at være af sammenlignelig kvalitet og at være bioækvivalent med Plavix.
English: Grepid can be started between seven days and six months after the stroke;
Danish: Behandlingen med Grepid kan påbegyndes 7 dage efter slagtilfældet og indtil 6 måneder efter,
English: This means that Grepid is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Danish: Det betyder, at Grepid er identisk med et referencelægemiddel, der allerede er godkendt i Den Europæiske Union, nemlig Plavix.
English: Grepid is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Danish: Grepid anvendes til forebyggelse af aterotrombotiske hændelser hos voksne (problemer forårsaget af blodpropper og åreforkalkning).
English: Grepid is a medicine that contains the active substance clopidogrel.
Danish: Grepid er et lægemiddel, der indeholder det aktive stof clopidogrel.
English: Why has Grepid been approved?
Danish: Hvorfor blev Grepid godkendt?
English: Because Grepid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Danish: Da Grepid er et generisk lægemiddel, der er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
English: What is Grepid?
Danish: Hvad er Grepid?
English: Because Grepid is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Danish: Da Grepid er et generisk lægemiddel, har undersøgelserne været begrænset til at påvise, at det er bioækvivalent med referencelægemidlet Plavix.
English: The active substance in Grepid, clopidogrel, is an inhibitor of platelet aggregation.
Danish: Det aktive stof i Grepid, clopidogrel, er et blodpladeaggregationshæmmende middel.
English: What is Grepid used for?
Danish: Hvad anvendes Grepid til?
English: How has Grepid been studied?
Danish: Hvordan blev Grepid undersøgt?
English: How is Grepid used?
Danish: Hvordan anvendes Grepid?
English: How does Grepid work?
Danish: Hvordan virker Grepid?
English: This is a summary of the European public assessment report (EPAR) for Zalmoxis.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Zalmoxis.
English: In this study, Zalmoxis was not compared with any other treatment.
Danish: I denne undersøgelse blev Zalmoxis ikke sammenlignet med noget andet lægemiddel.